

Evaluating Laser Photobiomodulation for the Treatment of Neuro-pathic Pain in Chemotherapy-induced Peripheral Neuropathy in Cancer Patients

NCT06834685

Status	RECRUITING
Phase	Not Applicable
Sponsor	Institut du Cancer de Montpellier - Val d'Aurelle
Enrollment	70 participants

Key Eligibility Criteria

Inclusion (9)

- Male or female aged 18 years minimum;
- Patient treated at the Montpellier Cancer Institute for a cancer (whatever the location) requiring a chemotherapy;
- Patient with significant NP defined as a score of 4 at the clinician-rated DN4 ;
- Patient with a NP for at least 3 months after the end of an adjuvant or neo-adjuvant chemotherapy;
- Women of childbearing potential must have a pregnancy urinary test within a maximum of 7 days before starting the study treatment. A negative result must be documented before study treatment is started. Women without reproductive potential are postmenopausal women or women who have undergone permanent sterilisation (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy);

... and 4 more (see full listing online)

Exclusion (17)

- Patient unable to come twice a week to the Montpellier Cancer Institute;
- Patient unable to sit for a 30-minutes period;
- Patient with an open wound or ulcer on the treatment area;
- Patient whose diagnosis of peripheral neuropathy is due to another cause (n.b., diabetes without neuropathy will not be a specific exclusion);
- Patient with uncontrolled psychiatric illness or neurocognitive impairment that may interfere with assessments, as the investigator clinical discretion;

... and 12 more (see full listing online)

Locations (1 total)

ICM, Montpellier, France